Genentech, Chiron Settle Herceptin Patent Dispute

Law360, New York (August 3, 2005, 12:00 AM EDT) -- Biotech companies Genentech, Inc. and Chiron have quietly settled the remaining patent disputes in a $300 million lawsuit over Genentech's metastatic breast cancer drug, Herceptin (Trastuzumab).

The deal was disclosed Tuesday by Genentech in a regulatory filing to the U.S. Securities and Exchange Commission.

Genentech and Chiron settled their dispute in June, ending both interference proceedings at the U.S. Patent & Trademark Office and a lawsuit that had been appealed to the U.S. Court of Appeals for the Federal Circuit.

“Under the settlement agreement, Chiron has...
To view the full article, register now.